Shangya Technology Co Ltd
Shangya Technology Co Ltd has a market price of 24.4 TWD and a market cap of 1,080,920,000 TWD, with a price-to-book ratio of 1.98 and a price-to-tangible-book ratio of 1.98. The company's liquidity is characterized by a current ratio of 3.09 and cash and equivalents of 187,585,000 TWD, indicating a relatively strong short-term liquidity position. However, the company reported negative operating cash flow of -44,153,000 TWD and free cash flow of -117,469,000 TWD, suggesting challenges in generating positive cash flow from operations. Profitability metrics show a return on equity of -0.1399 and a return on assets of -0.0869, indicating a loss-making position. The company's operating income is negative at -84,840,000 TWD, and net income is also negative at -76,310,000 TWD, which is below the industry median for profitability metrics. The debt-to-equity ratio of 0.33 suggests a relatively low level of leverage, which is favorable for financial stability. The company's revenue is derived from multiple segments, including Western medicine trading, solar power generation, real estate leasing, and power IC design, production, and sales. The geographic exposure is primarily within Taiwan, with sales to medical centers, public hospitals, foundation hospitals, and clinics, as well as to Taiwan power companies. The company's revenue concentration is not explicitly detailed, but the diverse business segments suggest a moderate level of diversification. The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The company's capital expenditure of -67,010,000 TWD indicates a reduction in investment, which may affect future growth potential. The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is low, and no significant adjustments have been applied to the valuation metrics. Recent events and filings do not indicate any significant changes in the company's operations or financial position. The company's business model and financial performance suggest a need for strategic adjustments to improve profitability and cash flow generation.
Business. Shangya Technology Co Ltd is a Taiwan-based company engaged in the provision of Western medicine products, including nervous system drugs, antineoplastic drugs, and cardiovascular system drugs, and operates in solar power generation, real estate leasing, and power IC design, production, and sales.
Classification. Shangya Technology Co Ltd is classified under the Healthcare economic sector, specifically in the Pharmaceuticals & Medical Research business sector, with a classification confidence of 0.92.
- Shangya Technology Co Ltd is a diversified company with operations in pharmaceuticals, solar power, real estate, and power IC design, but it is currently reporting losses.
- The company's liquidity position is strong, with a current ratio of 3.09 and significant cash and equivalents, but it is generating negative operating and free cash flows.
- Profitability metrics are negative, with a return on equity of -0.1399 and a return on assets of -0.0869, indicating a need for operational improvements.
- The company's debt-to-equity ratio is low at 0.33, which is favorable for financial stability.
- The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year.
- The risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected.
- --
- ## RATIONALES
- No immediate filing-based liquidity or dilution flags were detected.